Samlyn Capital, LLC Nurix Therapeutics, Inc. Transaction History
Samlyn Capital, LLC
- $6.07 Billion
- Q1 2025
A detailed history of Samlyn Capital, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 515,103 shares of NRIX stock, worth $5.03 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
515,103
Previous 515,840
0.14%
Holding current value
$5.03 Million
Previous $9.72 Million
37.03%
% of portfolio
0.1%
Previous 0.16%
Shares
4 transactions
Others Institutions Holding NRIX
# of Institutions
182Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$66.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$53.7 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$43.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$39.6 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$38.9 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $461M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...